Stephen Liu, MD, Georgetown University School of Medicine

Articles by Stephen Liu, MD, Georgetown University School of Medicine

The Future of Lung Cancer Treatment

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Mesothelioma: A Look at DREAM3R and PrECOG Trial

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Fundamentals of Mesothelioma

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Trials in Limited-Stage Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for Progressive Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in Small–Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Recent Advances in Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Understanding Immune Response in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Chemotherapy and Immunotherapy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Efficacy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Frontline Treatment in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Latest Updated Articles

Trials in Limited-Stage Small-Cell Lung Cancer
October 26th 2020
Fundamentals of Mesothelioma
October 26th 2020
Recent Advances in Small-Cell Lung Cancer
October 26th 2020
Understanding Immune Response in Non–Small Cell Lung Cancer
October 26th 2020
Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer
October 26th 2020
Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer
October 26th 2020

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

September Roundup of FDA Approvals in Oncology: 8 Decisions to Know

Two Dana-Farber Researchers Receive Prestigious New Innovator Award from the National Institutes of Health

Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC